Neumora Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

NMRA$0.47-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited, in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$40,520	$60,630	$131,395	$155,015
General and administrative	12,180	16,016	46,281	45,527
Acquired in-process research and development	5,000	—	5,000
Total operating expenses	57,700	76,646	182,676	200,542
Loss from operations	(57,700)	(76,646)	(182,676)	(200,542)
Other income (expense):
Interest income	1,685	4,209	7,009	15,845
Interest expense	(747)	—	(1,183)	—
Other expense, net	7	(57)	(498)	(93)
Total other income	945	4,152	5,328	15,752
Net loss before income taxes	(56,755)	(72,494)	(177,348)	(184,790)
Provision for income taxes	—	53	130	178
Net loss	(56,755)	(72,547)	(177,478)	(184,968)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	24	292	(53)	181
Comprehensive loss	$(56,731)	$(72,255)	$(177,531)	$(184,787)
Net loss per share, basic and diluted	$(0.35)	$(0.45)	$(1.10)	$(1.16)
Weighted-average shares outstanding, basic and diluted	161,838	159,576	161,663	158,837

The accompanying notes are an integral part of these condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.